Johnson & Johnson (NYSE:JNJ) Stock Price Down 1.7% – Time to Sell?

Johnson & Johnson (NYSE:JNJ) traded down 1.7% during mid-day trading on Tuesday . The stock traded as low as $253.17 and last traded at $254.2390. 7,698,584 shares changed hands during mid-day trading, a decline of 9% from the average daily volume of 8,499,445 shares. The stock had previously closed at $258.51.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J won a positive CHMP opinion for expanded use of its multiple myeloma drug Tecvayli, which could broaden the treatment’s commercial opportunity in Europe. Article Title
• Positive Sentiment: The stock hit a new 52-week high as biotech names rallied, highlighting investor enthusiasm for J&J’s healthcare exposure and pipeline strength. Article Title
• Positive Sentiment: J&J’s breakout past a recent buy point suggests technical momentum is improving and traders may be adding to positions. Article Title
• Positive Sentiment: Commentary that J&J remains attractive for dividend-focused investors points to continued support from income buyers and institutional accumulation. Article Title
• Positive Sentiment: Analyst and media pieces noting “fresh focus” on cancer-drug progress and a healthcare rally reinforce the idea that the market is rewarding J&J’s defensive growth profile. Article Title
• Neutral Sentiment: Several articles simply note that J&J is a heavily watched or trending stock, which adds attention but does not by itself change the fundamental outlook. Article Title
• Neutral Sentiment: Coverage asking whether there is still value after a big one-year rally reflects valuation debate, but it is more of a sentiment check than a direct catalyst. Article Title
• Negative Sentiment: The recent legal headlines remain a risk factor, even though J&J won the cited talc case; ongoing litigation keeps some overhang on the shares. Article Title

Wall Street Analyst Weigh In

A number of research firms have recently commented on JNJ. Leerink Partners raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 target price on the stock in a research note on Wednesday, May 13th. TD Cowen assumed coverage on Johnson & Johnson in a report on Wednesday, April 8th. They set a “buy” rating and a $250.00 price objective for the company. HSBC upped their price objective on Johnson & Johnson from $265.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Stifel Nicolaus increased their target price on Johnson & Johnson from $220.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, April 15th. Finally, Guggenheim lifted their target price on Johnson & Johnson from $266.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday. Twenty equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $256.70.

Johnson & Johnson Trading Down 1.7%

The stock’s 50-day moving average price is $231.39 and its 200 day moving average price is $230.03. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The firm has a market capitalization of $612.01 billion, a PE ratio of 29.39, a price-to-earnings-growth ratio of 2.49 and a beta of 0.26.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. During the same quarter in the previous year, the business earned $2.77 earnings per share. Johnson & Johnson’s quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were issued a $1.34 dividend. The ex-dividend date was Tuesday, May 26th. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio (DPR) is currently 61.97%.

Insider Activity at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares in the company, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Blueline Advisors LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $25,000. Cresta Advisors Ltd. purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $26,000. DecisionPoint Financial LLC raised its stake in Johnson & Johnson by 104.2% in the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after buying an additional 75 shares in the last quarter. Family CFO Inc bought a new position in Johnson & Johnson in the fourth quarter worth approximately $31,000. Finally, Bay Harbor Wealth Management LLC lifted its holdings in Johnson & Johnson by 49.0% during the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after buying an additional 49 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.